Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 4/2015

01.12.2015 | review

ASCO 2015: highlights in colorectal cancer

verfasst von: MD Wolfgang Eisterer

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten
share
TEILEN

Abstract

Two “first-in” studies of colorectal liver metastases were highlighted at the 2015 ASCO Annual Meeting: the first prospective randomized trial to evaluate radiofrequency ablation plus chemotherapy [J Clin Oncol 33] and the first large randomized phase III trial to study liver-directed selective internal radiation therapy [J Clin Oncol 33]. Radiofrequency ablation plus chemotherapy appeared to have clear benefit in this setting, whereas the results for selective internal radiotherapy in first-line therapy are currently less conclusive. Colorectal tumors that lacked the ability to repair DNA—or mismatch repair-deficient tumors—were found to be highly responsive to checkpoint blockade with the anti-programmed death 1 (PD-1) drug pembrolizumab, according to data from a phase II study [J Clin Onco 33]. Taregetd therapy with dual blockade of HER2/Neu with Trastuzumab and Lapatinib proved successful in in previously treated patients with HER2/Neu-positive tumors [J Clin Oncol 33].
Literatur
1.
Zurück zum Zitat Ruers T, Punt CJA, van Coevorden F, et al. Radiofrequency ablation combined with chemotherapy for unresectable colorectal liver metastases: Long-term survival results of a randomized phase II study of the EORTC-NCRI CCSG-ALM Intergroup 40004 (CLOCC). J Clin Oncol. 2015;33. (suppl; abstr 3501). Ruers T, Punt CJA, van Coevorden F, et al. Radiofrequency ablation combined with chemotherapy for unresectable colorectal liver metastases: Long-term survival results of a randomized phase II study of the EORTC-NCRI CCSG-ALM Intergroup 40004 (CLOCC). J Clin Oncol. 2015;33. (suppl; abstr 3501).
2.
Zurück zum Zitat Gibbs P, Heinemann V, Sharma NK, et al. SIRFLOX: Randomized phase III trial comparing first-line mFOLFOX6 ± bevacizumab versus mFOLFOX6 ± selective internal radiation therapy ± bevacizumab in patients with metastatic colorectal cancer. J Clin Oncol. 2015;33. (suppl; abstr 3502). Gibbs P, Heinemann V, Sharma NK, et al. SIRFLOX: Randomized phase III trial comparing first-line mFOLFOX6 ± bevacizumab versus mFOLFOX6 ± selective internal radiation therapy ± bevacizumab in patients with metastatic colorectal cancer. J Clin Oncol. 2015;33. (suppl; abstr 3502).
3.
Zurück zum Zitat Le DTL, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch repair deficiency. 2015 ASCO Annual Meeting. J Clin Oncol. 2015;33. (suppl; abstr LBA 100). Le DTL, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch repair deficiency. 2015 ASCO Annual Meeting. J Clin Oncol. 2015;33. (suppl; abstr LBA 100).
4.
Zurück zum Zitat Siena S, Sartore-Bianchi A, Lonardi S, et al. Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial. J Clin Oncol. 2015;33. (suppl; abstr 3508). Siena S, Sartore-Bianchi A, Lonardi S, et al. Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial. J Clin Oncol. 2015;33. (suppl; abstr 3508).
Metadaten
Titel
ASCO 2015: highlights in colorectal cancer
verfasst von
MD Wolfgang Eisterer
Publikationsdatum
01.12.2015
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2015
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-015-0243-3